<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453113</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP-2015-1840</org_study_id>
    <nct_id>NCT02453113</nct_id>
  </id_info>
  <brief_title>Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment</brief_title>
  <official_title>Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this is that the researcher can use low power Near Infrared laser treatment
      non-painful and non-damaging dose to changes the skin properties.The researcher can prove
      that signaling and a significant increase in the number of skin cells in skin tissue exposed
      to the laser can improve the human skin immune system to help improve human body response to
      vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researcher can use low power laser light one-minute exposures delivered to the skin at
      non-painful and non-damaging dose. The resulted in significant immunologic changes in the
      skin that included up-regulation of specific skin tissue and skin genes and the activation
      and mobilization of specific skin cells.

      In the first part of the study, the researcher will make a determination of the laser
      irradiance that will be tolerated. The highest irradiance the subject tolerates for 1 minute
      will be identified as that subject's maximum tolerable irradiance. After all subjects are
      tested, researcher will select the highest irradiance that was tolerated and use this in the
      second phase of the study.

      Approximately 24 hours after the first test exposures, each subject will receive a one minute
      laser treatment at the maximum tolerable irradiance. Four hours later, two skin biopsies will
      be collected from laser treated site a untreated.

      One tissue sample will be test at UC Irvine Dept. of Dermatopathology to evaluate microscopic
      skin changes, one skin sample will be delivered to Massachusetts General Hospital to evaluate
      RNA and protein expression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase the skin tissue to response to a vaccine</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vaccine Response Impaired</condition>
  <arm_group>
    <arm_group_label>low power laser</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low power laser</intervention_name>
    <description>Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment</description>
    <arm_group_label>low power laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women with skin type 1 and 2

          -  Not pregnant

        Exclusion Criteria:

          -  Use of systemic steroids, topical steroids, tanning solutions and anticoagulant

          -  History of HIV, mentally incompetent, prisoner, alcohol or drug impairment

          -  Abnormal photosensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brent Martin, MD</last_name>
    <phone>949.233-9060</phone>
    <email>bcmartin@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beckman Laser Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Martin, MD</last_name>
      <phone>949-233-9060</phone>
      <email>bcmartin@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Logan Thomas, MD</last_name>
      <email>lwthomas@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kristen Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brent Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montana Compton, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Elkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Logan Thomas, MS2</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Osann, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaccine and Immunotherapy Center Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Gelfand, MD</last_name>
      <phone>617-726-1796</phone>
      <email>jgelfand@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffery Gelfand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosalynn M Nazarian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Kristen Kelly, M.D., Professor Departments of Dermatology and Surgery</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

